Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NM 3086

X
Drug Profile

NM 3086

Alternative Names: NM-3086

Latest Information Update: 14 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovelMed Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Alternative complement pathway modulators; Complement C3-C5 convertases inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry age-related macular degeneration; Eye disorders; Macular degeneration; Paroxysmal nocturnal haemoglobinuria; Wet age-related macular degeneration

Highest Development Phases

  • Phase I Anaemia; Paroxysmal nocturnal haemoglobinuria
  • Preclinical Dry age-related macular degeneration; Wet age-related macular degeneration

Most Recent Events

  • 05 Jun 2023 Efficacy, pharmacodynamics and adverse events data from phase I trial in Paroxysmal nocturnal haemoglobinuria and Anaemia released by NovelMed
  • 06 Mar 2023 NM 3086 is available for licensing as of 06 Mar 2023. https://www.novelmed.com/partnersinvestors
  • 06 Mar 2023 Preclinical trials in Dry age-related macular degeneration in USA (Intravitreous) before March 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top